82 completed, 22 terminated, 5 withdrawn, 1 recruiting. 112 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 112 | Completed 82, Terminated 22, Withdrawn 5, Recruiting 1, Suspended 1, Unknown 1 |
| Phase 2 | 16 | Completed 10, Terminated 4, Recruiting 1, Suspended 1 |
Follow Tumors: new trials by email Literature Review of Tumors trials Research Report on Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HP Pyruvate MRI in Cancers Hyperpolarized 13C-Pyruvate - Image, Warburg Effect | Phase 1 / Phase 2 | Recruiting | University of Maryland, Baltimore | 25 | 2024-06-24 | 2025-09-22 |
| Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors ZN-c3, Bevacizumab, Pembrolizumab - Tumors, Ovarian Cancer | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-12-14 | 2023-06-15 | |
| CDK4/6 Tumor, Abemaciclib, Paclitaxel abemaciclib+paclitaxel - Tumors | Phase 1 / Phase 2 | Completed | Yonsei University | 30 | 2021-02-25 | 2024-12-18 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs TAS-102, Temozolomide, Filgrastim - Neuroendocrine Tumors, Neoplasms | Phase 1 | Terminated | University of Wisconsin, Madison | 18 | 2017-08-22 | 2022-09-23 |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer IT-141 - Cancer, Neoplasms | Phase 1 | Terminated | Intezyne Technologies, Inc. | 10 | 2017-03-23 | 2020-12-22 |
| Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors Lenvatinib, Midazolam - Tumors | Phase 1 | Completed | Eisai Inc. | 51 | 2016-04-18 | 2019-08-28 |
| A Phase I Study of PLX038 in Patients With Advanced Solid Tumors PLX038 - Tumors, Neoplasms | Phase 1 | Completed | ProLynx LLC | 40 | 2016-03-01 | 2023-07-12 |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors surufatinib - Tumors | Phase 1 / Phase 2 | Completed | Hutchmed | 130 | 2015-11-01 | 2024-07-10 |
| Study of E7046 in Subjects With Selected Advanced Malignancies E7046 - Tumors | Phase 1 | Terminated | Eisai Inc. | 31 | 2015-07-30 | 2020-02-17 |
| A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors Lenvatinib, Pembrolizumab - Tumors | Phase 1 / Phase 2 | Completed | Eisai Inc. | 357 | 2015-07-22 | 2023-07-20 |
| Safety Study of AMG 228 to Treat Solid Tumors AMG 228 - Advanced Malignancy, Advanced Solid Tumors | Phase 1 | Terminated | Amgen | 30 | 2015-04-21 | 2022-11-08 |
| Ph Ib/BGJ398/Cervix and Other Solid Tumors BGJ398, Carboplatin, Paclitaxel - Cancer of Cervix, Tumors | Phase 1 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2015-01-01 | 2015-02-16 | |
| Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma Lenvatinib, Ifosfamide, Etoposide - Tumors, Solid Malignant Tumors | Phase 1 / Phase 2 | Completed | Eisai Limited | 117 | 2014-12-29 | 2023-07-11 |
| A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma AMG 232, Trametinib, Dabrafenib - Advanced Malignancy, Advanced Solid Tumors | Phase 1 | Completed | Kartos Therapeutics, Inc. | 31 | 2014-12-19 | 2021-03-26 |
| Phase 1 Study of E7090 in Subjects With Solid Tumor E7090 - Tumors | Phase 1 | Completed | Eisai Co., Ltd. | 40 | 2014-10-28 | 2026-10-21 |
| to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage 188Re-BMEDA-liposome - Tumors | Phase 1 | Terminated | National Atomic Research Institute, Taiwan | 3 | 2014-10-01 | 2020-07-30 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors Volitinib(HMPL-504) - Tumors | Phase 1 | Completed | Hutchison Medipharma Limited | 85 | 2013-05-01 | 2019-07-15 |
| Phase I Study of LB-100 With Docetaxel in Solid Tumors LB-100 for Injection, Docetaxel - Tumors, Neoplasms | Phase 1 | Completed | Lixte Biotechnology Holdings, Inc. | 29 | 2013-02-01 | 2017-01-24 |
Showing 20 of 112. Sign in to see all of them.
Neoplasms (112) · Neoplasm Metastasis (10) · Lymphoma (9) · Breast Neoplasms (7) · Carcinoma (5) · Lung Neoplasms (5) · Ovarian Neoplasms (5) · Colorectal Neoplasms (4) · Melanoma (4) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4) · Sarcoma (4) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Recurrence (3)
Neoplasms by Histologic Type (26) · Neoplasms by Site (20) · Pathological Conditions, Signs and Symptoms (16) · Pathologic Processes (15) · Hemic and Lymphatic Diseases (14) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphoproliferative Disorders (12) · Neoplasms, Glandular and Epithelial (12) · Lymphatic Diseases (11) · Neoplastic Processes (11) · Urogenital Diseases (11) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Urogenital Neoplasms (10)
Paclitaxel (6) · Carboplatin (5) · Docetaxel (4) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (3) · Capecitabine (3) · Gemcitabine (3) · Irinotecan (3) · Topotecan (3) · brivanib (3) · epothilone B (3) · lenvatinib (3) · trebananib (3) · 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (2) · Bevacizumab (2) · Bortezomib (2)
Amgen (10) · Bristol-Myers Squibb (8) · Novartis Pharmaceuticals (6) · Merck Sharp & Dohme LLC (5) · AstraZeneca (3) · Eisai Inc. (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Agennix (2) · Astellas Pharma Inc (2) · Bayer (2) · Biogen (2) · Boehringer Ingelheim (2) · Kartos Therapeutics, Inc. (2) · Millennium Pharmaceuticals, Inc. (2) · Mirati Therapeutics Inc. (2)
United States (79) · Canada (12) · Japan (9) · France (8) · United Kingdom (7) · Spain (5) · Australia (4) · Belgium (4) · Italy (4) · China (2) · Germany (2) · Netherlands (2) · Switzerland (2) · Norway (1) · South Korea (1)
Gerald Batist, MD (2) · Gregory Reid, MSc, MBA (2) · Nina Bhardwaj, MD, PhD (2) · Aaron Mansfield, MD (1) · Abby Maizel, MD,PhD (1) · Anthony Tolcher, M.D. (1) · Anthony W. Tolcher, MD (1)
PMID 31401903, PMID 16622259, PMID 16818691, PMID 17517626, PMID 17557949, PMID 18077538, PMID 18202410, PMID 19192962, PMID 19203894, PMID 19238148, PMID 20110052, PMID 22210018, PMID 22234637, PMID 22371427, PMID 22884766, PMID 23400739, PMID 25428504, PMID 25795637, PMID 26155941, PMID 26755520, PMID 27139036, PMID 28039265, PMID 29423515, PMID 29980894, PMID 30073642, PMID 30077125, PMID 30219915, PMID 30242306, PMID 30922731, PMID 31204078, PMID 31358540, PMID 31542806, PMID 31647026, PMID 31961766, PMID 32067158, PMID 32167863, PMID 32554315, PMID 32554609, PMID 32586767, PMID 33241650, PMID 33568344, PMID 34039647, PMID 34143969, PMID 34416158, PMID 34416160, PMID 34562750, PMID 36608305, PMID 37074571, PMID 38242717, PMID 38967722
2017 (2), 2014 (1)